IN184589B
(US06373033-20020416-M00071.png)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
WO2001037804A2
(en)
*
|
1999-11-22 |
2001-05-31 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US20020041884A1
(en)
*
|
2000-03-07 |
2002-04-11 |
Evans Robert K. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
JP2005505429A
(ja)
*
|
2001-06-28 |
2005-02-24 |
マイクロチップス・インコーポレーテッド |
マイクロチップリザーバデバイスを密閉シーリングするための方法
|
AU2002353013A1
(en)
*
|
2001-12-03 |
2003-06-17 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
EP1534213B1
(en)
*
|
2002-03-13 |
2013-04-24 |
Sköld, Thomas |
Water-based delivery systems
|
US7510551B2
(en)
*
|
2002-08-16 |
2009-03-31 |
Microchips, Inc. |
Controlled release device and method using electrothermal ablation
|
US7497855B2
(en)
*
|
2002-09-04 |
2009-03-03 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
KR101152561B1
(ko)
*
|
2002-09-27 |
2012-06-01 |
파우더젝트 리서치 리미티드 |
핵산 코팅된 입자
|
AU2003284018A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
EP2526996B1
(en)
|
2002-12-20 |
2019-09-11 |
Xeris Pharmaceuticals, Inc. |
Formulation for intracutaneous injection
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
DE602004031011D1
(de)
*
|
2003-04-25 |
2011-02-24 |
Boston Scient Scimed Inc |
Feste arzneimittelformulierung und vorrichtung zu ihrer aufbewahrung und kontrollierten abgabe
|
US7892205B2
(en)
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
AU2004285603A1
(en)
*
|
2003-11-03 |
2005-05-12 |
Microchips, Inc. |
Medical device for sensing glucose
|
AU2005327211A1
(en)
*
|
2004-06-01 |
2006-08-17 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
US7537590B2
(en)
*
|
2004-07-30 |
2009-05-26 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
US7604628B2
(en)
*
|
2004-09-01 |
2009-10-20 |
Microchips, Inc. |
Multi-cap reservoir devices for controlled release or exposure of reservoir contents
|
WO2006031500A2
(en)
*
|
2004-09-10 |
2006-03-23 |
Becton, Dickinson And Company |
Reconstituting infusion device
|
US7488316B2
(en)
|
2005-01-25 |
2009-02-10 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
EP1962586B1
(en)
*
|
2005-12-22 |
2017-07-12 |
Oakwood Laboratories L.L.C. |
Sublimable sustained release delivery system and method of making same
|
CN101453982B
(zh)
|
2006-05-30 |
2011-05-04 |
精达制药公司 |
两件式内部通道渗透递送系统流动调节器
|
WO2008021133A2
(en)
|
2006-08-09 |
2008-02-21 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
KR20090130081A
(ko)
*
|
2007-03-30 |
2009-12-17 |
헬릭스 바이오파마 코포레이션 |
2상 지질-소포 조성물 및 질내 송달에 의한 자궁경부 이형성증의 치료 방법
|
EP2157967B1
(en)
|
2007-04-23 |
2013-01-16 |
Intarcia Therapeutics, Inc |
Suspension formulations of insulinotropic peptides and uses thereof
|
US8968786B2
(en)
|
2007-06-22 |
2015-03-03 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
WO2010056657A2
(en)
|
2008-11-16 |
2010-05-20 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
EP2398466B1
(en)
*
|
2008-11-24 |
2021-02-17 |
Massachusetts Institute of Technology |
Methods and compositions for localized nanoparticle delivery to a tumor
|
CN104323981B
(zh)
|
2009-09-28 |
2019-03-12 |
精达制药公司 |
基本稳态药物递送的快速建立和/或终止
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
JP5837519B2
(ja)
*
|
2010-03-09 |
2015-12-24 |
ヤンセン バイオテツク,インコーポレーテツド |
非水性高濃度減粘懸濁製剤
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
IN2012DN06581A
(US06373033-20020416-M00071.png)
|
2010-03-17 |
2015-10-23 |
Novaliq Gmbh |
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
SG193389A1
(en)
|
2011-03-10 |
2013-10-30 |
Xeris Pharmaceuticals Inc |
Stable formulations for parenteral injection of peptide drugs
|
ES2617968T3
(es)
|
2011-05-25 |
2017-06-20 |
Novaliq Gmbh |
Composición farmacéutica para la administración a uñas
|
PT3192501T
(pt)
|
2011-05-25 |
2020-07-31 |
Novaliq Gmbh |
Composição farmacêutica tópica à base de alcanos semifluorados
|
CN103930096B
(zh)
|
2011-10-31 |
2017-05-31 |
Xeris药物公司 |
用于治疗糖尿病的制剂
|
WO2013110621A1
(en)
|
2012-01-23 |
2013-08-01 |
Novaliq Gmbh |
Stabilised protein compositions based on semifluorinated alkanes
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
DE202013012742U1
(de)
|
2012-09-12 |
2019-01-22 |
Novaliq Gmbh |
Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen
|
KR102171897B1
(ko)
|
2012-09-12 |
2020-11-02 |
노바리크 게엠베하 |
부분불소화 알칸 조성물
|
EP2943479B1
(en)
|
2013-01-11 |
2020-04-15 |
Corsair Pharma, Inc. |
Prodrugs of treprostinil
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
SG11201505926VA
(en)
*
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
AU2014295052B2
(en)
|
2013-07-23 |
2018-08-30 |
Novaliq Gmbh |
Stabilized antibody compositions
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
EP3808338A1
(en)
|
2013-09-11 |
2021-04-21 |
Eagle Biologics, Inc. |
Liquid protein formulations containing ionic liquids
|
ES2904276T3
(es)
|
2013-09-27 |
2022-04-04 |
Massachusetts Inst Technology |
Nanoestructuras de proteínas biológicamente activas sin vehículo
|
TWI700101B
(zh)
*
|
2014-03-24 |
2020-08-01 |
美商百歐維拉提夫治療公司 |
凍乾之因子ix調配物
|
JP6561109B2
(ja)
|
2014-07-16 |
2019-08-14 |
コルセア ファーマ インコーポレイテッド |
トレプロスチニル誘導体化合物およびその使用方法
|
CA2957399C
(en)
|
2014-08-06 |
2023-09-26 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
WO2016196851A2
(en)
|
2015-06-03 |
2016-12-08 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
AU2016305087B2
(en)
|
2015-08-12 |
2022-01-20 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
DK3355990T3
(da)
|
2015-09-30 |
2019-09-16 |
Novaliq Gmbh |
Semifluorinerede forbindelser og disses sammensætninger
|
CN110693825B
(zh)
|
2015-09-30 |
2022-03-08 |
诺瓦利克有限责任公司 |
用于眼部给药的半氟化化合物
|
MX2018014016A
(es)
|
2016-05-16 |
2019-08-01 |
Intarcia Therapeutics Inc |
Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
EP3468581A1
(en)
|
2016-06-13 |
2019-04-17 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
WO2017220625A1
(en)
|
2016-06-23 |
2017-12-28 |
Novaliq Gmbh |
Topical administration method
|
CN116172987A
(zh)
|
2016-09-22 |
2023-05-30 |
诺瓦利克有限责任公司 |
用于治疗睑缘炎的药物组合物
|
KR20190057338A
(ko)
|
2016-09-23 |
2019-05-28 |
노바리크 게엠베하 |
시클로스포린을 포함하는 안과 조성물
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
ES2957559T3
(es)
|
2017-04-21 |
2024-01-22 |
Dermaliq Therapeutics Inc |
Composiciones de yodo
|
EP3621601A1
(en)
|
2017-05-12 |
2020-03-18 |
Novaliq GmbH |
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
EP3624846B1
(en)
|
2017-05-16 |
2024-08-07 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
|
WO2018222922A1
(en)
|
2017-06-02 |
2018-12-06 |
Xeris Pharmaceuticals, Inc. |
Precipitation resistant small molecule drug formulations
|
AU2018328209A1
(en)
|
2017-09-05 |
2020-04-23 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
US11723861B2
(en)
|
2017-09-27 |
2023-08-15 |
Novaliq Gmbh |
Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
|
CN111182893A
(zh)
|
2017-10-04 |
2020-05-19 |
诺瓦利克有限责任公司 |
包含f6h8的眼用组合物
|
CN112135603B
(zh)
|
2018-03-02 |
2024-04-16 |
诺瓦利克有限责任公司 |
包含奈必洛尔的药物组合物
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
AU2019358249B2
(en)
|
2018-10-12 |
2024-02-22 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
EP3921082A4
(en)
|
2019-02-05 |
2022-11-02 |
Lindy Biosciences, Inc. |
ISOLATED CELL CULTURE COMPONENTS AND METHODS OF ISOLATION THEREOF FROM LIQUID CELL CULTURE MEDIUM
|
US20220409705A1
(en)
|
2019-12-06 |
2022-12-29 |
Guangzhou Bioseal Biotech Co., Ltd. |
Flowable fibrinogen thrombin paste
|
WO2023044455A2
(en)
*
|
2021-09-16 |
2023-03-23 |
Team Medical Llc |
Rna stabilization
|